Capricor Therapeutics (NASDAQ:CAPR) Releases Earnings Results, Misses Expectations By $0.59 EPS

Capricor Therapeutics (NASDAQ:CAPR) released its earnings results on Tuesday. The biotechnology company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.59), FiscalAI reports.

Capricor Therapeutics Stock Down 9.9%

Shares of Capricor Therapeutics stock traded down $0.98 during trading on Tuesday, reaching $8.87. 4,307,808 shares of the stock were exchanged, compared to its average volume of 3,158,908. The stock’s fifty day moving average is $8.09 and its 200 day moving average is $20.13. The firm has a market cap of $515.70 million, a price-to-earnings ratio of -3.62 and a beta of 0.80. Capricor Therapeutics has a 1 year low of $2.96 and a 1 year high of $40.37.

Analysts Set New Price Targets

Several equities analysts recently issued reports on CAPR shares. B. Riley Financial upgraded Capricor Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $5.00 to $21.00 in a research report on Monday, September 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Friday, September 11th. Piper Sandler raised Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Tuesday, September 1st. Cantor Fitzgerald upgraded shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Friday, August 14th. Finally, Wall Street Zen cut shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Capricor Therapeutics currently has an average rating of “Hold” and an average price target of $30.25.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage. Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.